Shire’s NPS Buy Ahead Of FDA Natpara Vote Underscores Deal’s Logic
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire says it aims to use NPS’s rare-disease focus and pipeline to expand its expertise in gastrointestinal diseases - and voices confidence FDA will approve target’s Natpara drug to treat hypoparathyroidism.